RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human pharmacology research

CJC-1295 with DAC research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

Early controlled studies examined the long-acting growth hormone-releasing hormone analogue CJC-1295, including its pharmacokinetic profile and patterns of growth-hormone and IGF-I secretion.

Areas studied

  • Pharmacokinetic profile
  • Growth-hormone secretion patterns
  • IGF-I response
  • Growth-hormone pulsatility

Limitations and investigational status

The cited studies were small, early pharmacology trials in healthy adults. They do not establish therapeutic efficacy and should not be extrapolated to CJC-1295 without DAC or other differently modified GHRH analogues.

References

  1. 1Teichman et al. — Journal of Clinical Endocrinology & Metabolism, 2006
  2. 2Ionescu and Frohman — Journal of Clinical Endocrinology & Metabolism, 2006

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.